Ranibizumab in neovascular age-related macular degeneration

Neovascular age-related macular degeneration (AMD) is a visually devastating condition resulting from choroidal neovascularization and secondary photoreceptor loss. Ranibizumab and bevacizumab are medications that target vascular endothelial growth factor (VEGF). While other therapies have demonstrated some ability to reduce the risk of losing vision from neovascular AMD, most patients continue to lose some degree of central visual acuity. There is growing evidence that intravitreal administration of ranibizumab and bevacizumab is effective in significantly improving the visual acuity in patients with neovascular age-related macular degeneration.

[1]  R. Klein,et al.  Prevalence of age-related maculopathy. The Beaver Dam Eye Study. , 1992, Ophthalmology.

[2]  J. Hardcastle,et al.  Colorectal cancer , 1993, Europe Against Cancer European Commission Series for General Practitioners.

[3]  J. Folkman,et al.  Increased Vascular Endothelial Growth Factor Levels in the Vitreous of Eyes With Proliferative Diabetic Retinopathy , 1995 .

[4]  L. Aiello,et al.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.

[5]  Vascular Endothelial Growth Factor In Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders , 1995 .

[6]  E S Gragoudas,et al.  Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. , 1996, Archives of ophthalmology.

[7]  R. Danis,et al.  Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. , 1996, Ophthalmology.

[8]  Joan W. Miller,et al.  Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. , 1996, Archives of ophthalmology.

[9]  S. Seregard,et al.  Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. , 1996, Investigative ophthalmology & visual science.

[10]  T J Flotte,et al.  Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey. , 1999, Ophthalmology.

[11]  R. Cuthbertson,et al.  Comparisons of the Intraocular Tissue Distribution, Pharmacokinetics, and Safety of 125I-Labeled Full-Length and Fab Antibodies in Rhesus Monkeys Following Intravitreal Administration , 1999, Toxicologic pathology.

[12]  Joan W. Miller,et al.  Photodynamic therapy using Lu-Tex induces apoptosis in vitro, and its effect is potentiated by angiostatin in retinal capillary endothelial cells. , 2000, Investigative ophthalmology & visual science.

[13]  M. Gillies,et al.  Triamcinolone acetonide modulates permeability and intercellular adhesion molecule‐1 (ICAM‐1) expression of the ECV304 cell line: implications for macular degeneration , 2000, Clinical and experimental immunology.

[14]  R. Danis,et al.  Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. , 2001, Archives of ophthalmology.

[15]  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. , 2001 .

[16]  Christopher J. Robinson,et al.  The splice variants of vascular endothelial growth factor (VEGF) and their receptors. , 2001, Journal of cell science.

[17]  Jennifer I. Lim,et al.  A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. , 2001, Archives of ophthalmology.

[18]  Joan W. Miller,et al.  Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. , 2002, Archives of ophthalmology.

[19]  Joan W. Miller,et al.  VEGF164-mediated Inflammation Is Required for Pathological, but Not Physiological, Ischemia-induced Retinal Neovascularization , 2003, The Journal of experimental medicine.

[20]  J. Sorenson,et al.  Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. , 2003, Ophthalmology.

[21]  Michael Stur,et al.  Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. , 2003, American journal of ophthalmology.

[22]  J. Slakter,et al.  Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. , 2003, Ophthalmology.

[23]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[24]  Michael D. Ober,et al.  Intravitreal triamcinolone acetonide and intraocular pressure. , 2004, American journal of ophthalmology.

[25]  A. Larsson,et al.  Serum and plasma levels of FGF-2 and VEGF in healthy blood donors , 2004, Angiogenesis.

[26]  M. Hartnett,et al.  VEGF isoforms and their expression after a single episode of hypoxia or repeated fluctuations between hyperoxia and hypoxia: relevance to clinical ROP. , 2004, Molecular vision.

[27]  W. Amoaku,et al.  Treatment of Age-Related Macular Degeneration , 2004, Journal of the Royal Society of Medicine.

[28]  E. Gragoudas,et al.  Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.

[29]  A. Ho.  Effect of Lesion Size, Visual Acuity, and Lesion Composition on Visual Acuity Change With and Without Verteporfin Therapy for Choroidal Neovascularization Secondary To Age-Related Macular Degeneration: TAP and VIP Report No. 1 , 2004 .

[30]  David J. Wilson,et al.  Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: ophthalmic findings: SST report no. 11. , 2004, Ophthalmology.

[31]  Philip J Rosenfeld,et al.  Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. , 2005, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye.

[32]  P. Rosenfeld,et al.  Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. , 2005, Ophthalmology.

[33]  P. Rosenfeld,et al.  Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. , 2005, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye.

[34]  D. Fei,et al.  Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. , 2005, Investigative ophthalmology & visual science.

[35]  Ivana K. Kim,et al.  Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. , 2005, Archives of ophthalmology.

[36]  M. Blumenkranz,et al.  Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. , 2005, Ophthalmology.

[37]  P. Rosenfeld,et al.  Visual Acuity Outcomes Following a Variable–Dosing Regimen for Ranibizumab (LucentisTM) in Neovascular AMD: The PrONTO Study , 2006 .

[38]  R. Spaide,et al.  INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF PROLIFERATIVE DIABETIC RETINOPATHY COMPLICATED BY VITREOUS HEMORRHAGE , 2006, Retina.

[39]  J. Slakter,et al.  INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF MACULAR EDEMA IN CENTRAL RETINAL VEIN OCCLUSION: A Short-Term Study , 2006, Retina.

[40]  Richard F Spaide,et al.  INTRAVITREAL BEVACIZUMAB TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION , 2006, Retina.

[41]  Susan Schneider,et al.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[42]  R. Avery.  Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. , 2006, Retina.

[43]  R. Maturi,et al.  ELECTROPHYSIOLOGIC FINDINGS AFTER INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT , 2006, Retina.

[44]  I. Perlman,et al.  ELECTROPHYSIOLOGIC AND RETINAL PENETRATION STUDIES FOLLOWING INTRAVITREAL INJECTION OF BEVACIZUMAB (AVASTIN) , 2006, Retina.

[45]  Joan W. Miller,et al.  Randomized, Controlled Phase III Study of Ranibizumab (LucentisTM) for Minimally Classic or Occult Neovascular Age–Related Macular Degeneration: Two–Year Efficacy Results of the MARINA Study , 2006 .

[46]  R. Avery,et al.  Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. , 2006, Ophthalmology.

[47]  G. Peyman,et al.  TESTING INTRAVITREAL TOXICITY OF BEVACIZUMAB (AVASTIN) , 2006, Retina.

[48]  F. Davidorf,et al.  Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. , 2006, Retina.

[49]  T. Ciulla,et al.  Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. , 2006, Archives of ophthalmology.

[50]  Ma Dong,et al.  Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .

[51]  Michael A. Albert,et al.  Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema. , 2006, Retina.

[52]  J. Slakter,et al.  Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. , 2006, Ophthalmology.

[53]  J. Giráldez,et al.  Ranibizumab for neovascular age-related macular degeneration. , 2008, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[54]  S. Roth,et al.  Clinical Interventions in Aging , 2022 .